


IN THE CLAIMS

Please amend the claims as follows:

1. (Previously Presented) A compound of formula (I):



wherein

A is CH;

X is F, Cl, or Br;


Y is hydrogen, hydroxy, or (C₁-C₇)alkoxy; and

Z is an amino acid, or heterocycle;

or a pharmaceutically acceptable salt thereof.

2. (Original) The compound of claim 1, wherein Y is H.
3. (Original) The compound of claim 1, wherein Y is -OH.
4. (Original) The compound of claim 1, wherein Y is -OMe.
5. (Original) The compound of any of claims 1 to 4 wherein X is -Cl.
6. (Original) The compound of any of claims 1 to 4 wherein X is -Br.
7. (Original) The compound of any of claims 1 to 6 wherein Z is an amino acid.

8. (Original) The compound of any of claims 1 to 6 wherein Z is $-\text{NH}-(\text{CH}_2)_2-\text{SO}_3\text{H}$.
9. (Original) The compound of any of claims 1 to 6 wherein Z is $-\text{NH}-\text{CH}_2-\text{CO}_2\text{H}$.
10. (Original) The compound of any of claims 1 to 6 wherein Z is $-\text{NH}-\text{CH}(\text{CH}_3)-\text{CO}_2\text{H}$.
11. (Original) The compound of any of claims 1 to 6 wherein Z is a nitrogen linked pyrrolidino, piperidino, morpholino, 1,3-benzodiazepino, 1,4-benzodiazepino, or 1,5-benzodiazepino.
12. (Original) A compound of formula (I):



wherein

A is CH;

X is F, Cl, or Br;


Y is hydroxy, or (C₁-C₇)alkoxy; and

Z is an -NR_aR_b;

where R_a and R_b is independently hydrogen, (C₁-C₇)alkyl, (C₁-C₇)alkanoyl, aryl, aryl(C₁-C₇)alkyl, or where R_a and R_b together with the nitrogen to which they are attached are a pyrrolidino, piperidino, morpholino, 1,3-benzodiazepino, 1,4-benzodiazepino, or 1,5-benzodiazepino;
or a pharmaceutically acceptable salt thereof.

13. (Original) The compound of claim 12, wherein Y is -OH.
14. (Original) The compound of claim 12, wherein Y is -OMe.

15. (Original) The compound of any of claims 12 to 14 wherein X is -Cl.
16. (Original) The compound of any of claims 12 to 14 wherein X is -Br.
17. (Original) The compound of any of claims 12 to 16 wherein Z is -NR_aR_b.
18. (Original) The compound of any of claims 12 to 16 wherein Z is -NH₂.
19. (Original) The compound of any of claims 12 to 16 wherein Z is -NHCH₃.
20. (Original) The compound of any of claims 12 to 16 wherein Z is a nitrogen linked 1,3-benzodiazepino, 1,4-benzodiazepino, or 1,5-benzodiazepino.
21. (Original) A compound of formula (I):



wherein

A is CH;

X is F, Cl, or Br;

Y is hydrogen, hydroxy, or (C₁-C₇)alkoxy; and

Z is -NR_aR_b; and 0

R_a and R_b are each independently hydrogen, (C₁-C₇)alkyl, (C₁-C₇)alkanoyl, aryl, aryl(C₁-C₇)alkyl, or where R_a and R_b together with the nitrogen to which they are attached are a pyrrolidino, piperidino, morpholino, 1,3-benzodiazepino, 1,4-benzodiazepino, or 1,5-benzodiazepino;
or a pharmaceutically acceptable salt thereof.

22. (Original) The compound of claim 21 wherein R_a and R_b are each independently (C₁-C₇)alkanoyl, aryl, aryl(C₁-C₇)alkyl, or where R_a and R_b together with the nitrogen to which they are attached are a pyrrolidino, piperidino, morpholino, 1,3-benzodiazepino, 1,4-benzodiazepino, or 1,5-benzodiazepino.
23. (Original) The compound of claim 21 or 22 wherein Y is H.
24. (Original) The compound of claim 21 or 22 wherein Y is -OH.
25. (Original) The compound of claim 21 or 22 wherein Y is -OMe.
26. (Original) The compound of any of claims 21 to 25 wherein X is -Cl.
27. (Original) The compound of any of claims 21 to 25 wherein X is -Br.
28. (Original) The compound of any of claims 21 to 27 wherein Z is -NR_aR_b.
29. (Original) The compound of any of claims 21 to 27 wherein Z is a nitrogen linked pyrrolidino, piperidino, or morpholino.
30. (Original) The compound of any of claims 21 to 27 wherein Z is a nitrogen linked 1,3-benzodiazepino, 1,4-benzodiazepino, or 1,5-benzodiazepino.
- 31-48. (Cancelled)
49. (Previously Presented) The compound
2-{4-((7-Bromo-2-quinolinyl)oxy)phenoxy} propionmethanamide;
2-{4-((7-Chloro-2-quinolinyl)oxy)phenoxy} propiondimethanamide;
(2-(4-(7-Bromo-2-quinolinyl)oxy)phenoxy) propionylamino ethanesulfonic acid;
{2-{4-(7-Bromo-quinolin-2-yl)oxy}phenoxy} propionylamino} acetic acid;

(R) (2-(4-(7-Bromo-2-quinolinyl)oxy)phenoxy) propionylamino ethanesulfonic acid;
(R) {2-[4-(7-Bromo-quinolin-2-yloxy)-phenoxy]-propionylamino} acetic acid;
or pharmaceutically acceptable salts thereof.

50. (Previously Presented) The compound of any of claims 1 to 30 or 49 which is the (R) enantiomer.

51. (Previously Presented) The compound of any of claims 1 to 30 or 49 which is the (S) enantiomer.

52. (Previously Presented) The compound of any of claims 1 to 30 or 49 to 51 which the compound is isolated and purified.

53. (Withdrawn) The compound of claim 52, wherein the compound is a solid.

54. (Withdrawn) The compound of claim 52, wherein the compound is a crystalline solid.

55. (Currently Amended) A pharmaceutical composition comprising a compound any one of claims 1 to 30 or 49 to 54 and a pharmaceutically acceptable diluent or carrier.

56. (Withdrawn) The pharmaceutical composition of claim 55, wherein the pharmaceutical composition is formulated as a unit dosage form.

57. (Withdrawn) The pharmaceutical composition of claim 56, wherein the unit dosage form is formulated for oral administration.

58. (Withdrawn) The pharmaceutical composition of claim 56, wherein the unit dosage form is formulated for administration by injection.

59-60. (Cancelled)

61-64. (Cancelled)